Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma
- 22 November 2004
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 128 (2) , 177-183
- https://doi.org/10.1111/j.1365-2141.2004.05284.x
Abstract
The majority of the available data on primary central nervous system lymphoma (PCNSL) derive from small unicentric or oligocentric studies. In this multicentre study, we evaluated the response, survival and toxicity in PCNSL patients after carmustine, methotrexate 1.5 g/m2, procarbazine and dexamethasone (BMPD) chemotherapy and searched for prognostic factors. Fifty-six patients received the BMPD protocol (dexamethasone was given only in course 1). The overall complete response rate to chemotherapy was 61% (34/56). Ten complete responders received whole-brain irradiation and 24 were not irradiated. Responders to chemotherapy had significantly longer median overall survival than non-responders (18.2 vs. 9.9 months, P = 0.02). Median survival was significantly longer at institutions accruing at least four patients than at those with fewer patients (31.5 vs. 9.5 months, P = 0.03).Keywords
This publication has 22 references indexed in Scilit:
- High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non–AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962Journal of Clinical Oncology, 2003
- Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group ExperienceJournal of Clinical Oncology, 2003
- Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10Journal of Clinical Oncology, 2002
- A multicenter study of treatment of primary CNS lymphomaNeurology, 2002
- Therapeutic management of primary central nervous system lymphoma: Lessons from prospective trialsAnnals of Oncology, 2000
- Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosisCancer Chemotherapy and Pharmacology, 2000
- Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomasJournal of Neurosurgery, 1999
- Primary central nervous system non-hodgkin’s lymphoma (PCNSL): survival advantages with combined initial therapy? a final report of the north central cancer treatment group (NCCTG) study 86-72-52International Journal of Radiation Oncology*Biology*Physics, 1999
- Successful Treatment of Non-Hodgkin's Lymphoma of the Central Nervous System with BMPD Chemotherapy Followed by RadiotherapyLeukemia & Lymphoma, 1998
- Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarrazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final reportInternational Journal of Radiation Oncology*Biology*Physics, 1990